Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25758262 | 0.94 | TRPA1 (0.39) | TRPA1TRPM8GBA1 | |
| SCHEMBL349547 | 0.91 | GBA1 (0.42) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL26177769 | 0.88 | TRPA1 (0.42) | TRPA1TRPM8GBA1 | |
| SCHEMBL26224684 | 0.85 | TRPA1 (0.42) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL18720931 | 0.78 | TRPA1 (0.42) | TRPA1TRPM8 | |
| SCHEMBL1132298 | 0.78 | CA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL29296321 | 0.77 | TRPA1 (0.35) | TRPA1TRPM8GBA1 | |
| SCHEMBL16191447 | 0.77 | TRPA1 (0.37) | TRPA1TRPM8 | |
| SCHEMBL14639771 | 0.76 | CA1 (0.48) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL6902583 | 0.76 | CA1 (0.42) | TRPA1TRPM8GBA1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | TRPA1 3636/4885TRPM8 4005/4885GBA1 496/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | TRPA1 3512/4885TRPM8 3977/4885GBA1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.